相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative Transcriptomic Analysis of Archival Human Vestibular Schwannoma Tissue from Patients with and without Tinnitus
Krishna Bommakanti et al.
JOURNAL OF CLINICAL MEDICINE (2023)
Real-world evidence for preventive effects of statins on cancer incidence: A trans-Atlantic analysis
Bjoern-O Gohlke et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
A Critical Overview of Targeted Therapies for Vestibular Schwannoma
Ryota Tamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation
Scott R. Plotkin et al.
GENETICS IN MEDICINE (2022)
Association of Metformin With the Growth of Vestibular Schwannomas
Sophia Tran et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2021)
Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis
Jianwei Shi et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2021)
A Review of Drug Therapy in Vestibular Schwannoma
Jianfei Long et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Targeted Therapies for the Neurofibromatoses
Lauren D. Sanchez et al.
CANCERS (2021)
Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects
Yu Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Vestibular Schwannomas
Matthew L. Carlson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
The Natural History of Vestibular Schwannoma and When to Intervene
Donald Tan et al.
CURRENT OTORHINOLARYNGOLOGY REPORTS (2021)
Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
Huan Jia et al.
CURRENT OTORHINOLARYNGOLOGY REPORTS (2021)
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Masazumi Fujii et al.
CURRENT ONCOLOGY (2021)
EANO guideline on the diagnosis and treatment of vestibular schwannoma
Roland Goldbrunner et al.
NEURO-ONCOLOGY (2020)
Pro-inflammatory TNF-α and IFN-γ Promote Tumor Growth and Metastasis via Induction of MACC1
Dennis Kobelt et al.
FRONTIERS IN IMMUNOLOGY (2020)
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Jonas Feldheim et al.
CANCERS (2020)
Analysis of ADAM9 regulation and function in vestibular schwannoma primary cells
Anja Nattmann et al.
BMC RESEARCH NOTES (2020)
NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss
Jessica E. Sagers et al.
HEARING RESEARCH (2019)
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response
Carsten Hagemann et al.
CANCERS (2019)
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models
Yingchao Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CXCR4: A new player in vestibular schwannoma pathogenesis
Maria Breun et al.
Oncotarget (2018)
MACC1-the first decade of a key metastasis molecule from gene discovery to clinical translation
Harikrishnan Radhakrishnan et al.
CANCER AND METASTASIS REVIEWS (2018)
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients
Jonas Feldheim et al.
ONCOTARGETS AND THERAPY (2018)
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells
Marisa A. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1
Manisha Juneja et al.
PLOS BIOLOGY (2017)
The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors
L. Zhou et al.
ONCOGENE (2016)
The importance of nerve microenvironment for schwannoma development
Alexander Schulz et al.
ACTA NEUROPATHOLOGICA (2016)
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O. Blakeley et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
When Does Hearing Loss Occur in Vestibular Schwannoma Surgery? Importance of Auditory Brainstem Response Changes in Early Postoperative Phase
Maria Hummel et al.
WORLD NEUROSURGERY (2016)
Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells
Sonam Dilwali et al.
CANCER BIOLOGY & THERAPY (2015)
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients
Adam Hexter et al.
JOURNAL OF MEDICAL GENETICS (2015)
MACC1 overexpression and survival in solid tumors: a meta-analysis
Gang Wang et al.
TUMOR BIOLOGY (2015)
Systemic therapy in neurofibromatosis type 2
Stephanie Hui-Su Lim et al.
CANCER TREATMENT REVIEWS (2014)
Molecular insights into NF2/Merlin tumor suppressor function
Jonathan Cooper et al.
FEBS LETTERS (2014)
A neuronal function of the tumor suppressor protein merlin
Alexander Schulz et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation
Miguel Torres-Martin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Impact of MACC1 on human malignant glioma progression and patients unfavorable prognosis
Carsten Hagemann et al.
NEURO-ONCOLOGY (2013)
Clinical features of intracranial vestibular schwannomas
Xiang Huang et al.
ONCOLOGY LETTERS (2013)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Growth Characteristics of Vestibular Schwannomas
David A. Moffat et al.
OTOLOGY & NEUROTOLOGY (2012)
Mechanisms of Hearing Loss in Neurofibromatosis Type 2
Ashok R. Asthagiri et al.
PLOS ONE (2012)
Novel Autosomal Recessive Nonsyndromic Hearing Impairment Locus DFNB90 Maps to 7p22.1-p15.3
Ghazanfar Ali et al.
HUMAN HEREDITY (2011)
A prospective study of hearing preservation in untreated vestibular schwannomas Clinical article
Michael E. Sughrue et al.
JOURNAL OF NEUROSURGERY (2011)
Noncoding Mutations of HGF Are Associated with Nonsyndromic Hearing Loss, DFNB39
Julie M. Schultz et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation
Luigi Franchi et al.
JOURNAL OF IMMUNOLOGY (2009)
Neurofibromatosis type 2
Ashok R. Asthagiri et al.
LANCET (2009)
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
Ulrike Stein et al.
NATURE MEDICINE (2009)
Magic but treatable? Tumours due to loss of Merlin
C. O. Hanemann
BRAIN (2008)
Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification
Gareth R. Evans et al.
JOURNAL OF MEDICAL GENETICS (2007)
Differential gene expression between human schwannoma and control Schwann cells
C. O. Hanemann et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2006)
Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought
DGR Evans et al.
OTOLOGY & NEUROTOLOGY (2005)
Hearing changes after diagnosis in neurofibromatosis Type 2
A Masuda et al.
OTOLOGY & NEUROTOLOGY (2004)
Hearing deterioration in patients with a non-growing vestibular schwannoma
K Graamans et al.
ACTA OTO-LARYNGOLOGICA (2003)
分享论文
